Risperidone: An assessment of its economic benefits in the treatment of schizophrenia

Journal of Medical Economics

Volumn 1, Issue 1-4, 1998, Pages 103-134

  Cookson, Ronald F ^a   Huybrechts, Krista F ^b  

^a Caro Research ^*  (United Kingdom)

^b CARO RESEARCH INSTITUTE   (United States)

Author keywords

antipsychotics; costs; pharmacoeconomics; risperidone; schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; AUSTRALIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSKINESIA; DYSTONIA; EUROPE; FEMALE; HEMATOLOGIC DISEASE; HOSPITAL COST; HOSPITALIZATION; HUMAN; MALE; META ANALYSIS; NORTH AMERICA; PARKINSON DISEASE; RELAPSE; RESOURCE MANAGEMENT; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 0031757905     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/199801103134     Document Type: Review

References (62)

1. Kane, JM, Freeman, HL, Towards more effective antipsychotic treatment. British Journal of Psychiatry, 1994. 165(Suppl 25):22-31. (Pubitemid 24331670)
2. Knapp, M, Kavanagh, S, Economic Outcomes and Costs in the Treatment of Schizophrenia. Clinical Therapeutics, 1997. 19(1):128-138. (Pubitemid 27186445)
3. Williams, R, Dickson, RA, Economics of Schizophrenia. Canadian Journal of Psychiatry, 1995. 40 (7 Suppl 2): S60-67.
4. UK Clinical Standards Advisory Group, Schizophrenia Volume 1, August 1995.
5. Glennie, JL, Pharmacoeconomic evaluations of clozapine in treatmentresistant schizophrenia and risperidone in chronic schizophrenia, 1997, Canadian Coordinating Centre for Health Technology Assessment (CCOHTA): Ottawa, Ontario.
6. Chew, R, Compendium of Health Statistics, 1995, Office of Health Economics, London.
7. Kerwin, RW, An essay on the use of new antipsychotics. Psychiatric Bulletin, 1996. 20:23-26.
8. Viale, GL, Evaluating the cost effectiveness of newer psychotropic medications. American Journal of Managed Care, 1997;3:S7-S10.
9. Schatzberg, A, Nemeroff, C, eds. Textbook of Psychopharmacology. 1995, American Psychiatric Press: Washington DC.
10. Weiden, PJ, Olfson, M, Cost of relapse in schizophrenia. Schizophrenia Bulletin, 1995. 21(3):419-429.
11. Shepherd, M, Watt, D, Falloon, I, et al., The natural history of schizophrenia. A five year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine, 1989(Monograph Supplement 15):1-46. (Pubitemid 19234086)
12. Mason, P, Wild, D, Cookson, RF, et al., Measuring quality of life in people with schizophrenia. British Journal of Psychiatry (submitted), 1998.
13. Awad, AG, Voruganti, L N P, Heslegrave, RJ, Measuring quality of life in patients with schizophrenia. Pharmacoeconomics, 1997. 11(1):32-47. (Pubitemid 27032248)
14. Franz, M, Lis, S, Pluddemann, K, et al., Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. British Journal of Psychiatry, 1997. 170:422-425. (Pubitemid 27224537)
15. Glazer, WM, The impact of managed care systems on relapse prevention and quality of life for patients with schizophrenia. European Neuropsychopharmacology, 1996. 6(S2):35-39.
16. Bosanquet, N, Schizophrenia: developing new strategies for effective care. British Journal of Medical Economics, 1995. 8:51-64.
17. Soumerai, SB, McLaughlin, TJ, Ross-Degnan, D, et al., Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine, 1994. 331:650-5. (Pubitemid 24276866)
18. Chisholm, D, Healey, A, Knapp, M, QALYs and mental health care. Mental Health Research Review, 1995. 2:17-19.
19. Eli Lilly and Company Limited, Olanzapine Product Monograph, 1996: Basingstoke UK.
20. Wirshing WC and Marder SR, Efficacy and dosing issues of novel antipsychotics. Int J Psychiatry in Clinical Practice, 1998(2):S35-S38;
21. Farde L and Nyberg S, Dosing determination for novel antipsychotics: a PET based approach. Int J Psychiatry in Clinical Practice, 1998(2):S39-S42
22. Lieberman, JA, Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. Journal of Clinical Psychiatry, 1996. 57(Suppl 11):68-71. (Pubitemid 26389788)
23. Goldberg, D, Cost-effectiveness studies in the treatment of schizophrenia. Schizophrenia Bulletin, 1991. 17(3):453-459.
24. Guest, JF, Hart, WM, Cookson, RF, et al., Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. British Journal of Medical Economics, 1996. 10:59-67. (Pubitemid 26141313)
25. Davies, LM, Drummond, MF, Economics and schizophrenia: the real cost. British Journal of Psychiatry, 1995. 165(25):18-21. (Pubitemid 24331669)
26. Knapp, M, Beecham, J, Anderson, J, et al., The TAPS project. 3. Predicting the community costs of closing psychiatric hospitals. British Journal of Psychiatry, 1990. 157:661-670. (Pubitemid 20360961)
27. Knapp, M, Chisholm, D, Astin, J, et al., The cost consequences of changing the hospitalcommunity balance: the mental health residential care study. Psychological Medicine, 1997. 27(3):681-692. (Pubitemid 27216193)
28. Gray, AM, Marshall, M, Lockwood, A, et al., Problems in conducting economic evaluations alongside clinical trials: Lessons from a study of case management for people with mental disorders. British Journal of Psychiatry, 1997. 170:47-52. (Pubitemid 27404778)
29. Lindstrom, E, Eriksson, B, Hellgren, A, et al., Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clinical Therapeutics, 1995. 17(3):402-412.
30. Hart, WM, Lindstrom, E, Guest, JF, Economic impact of the use of risperidone for the treatment of chronic schizophrenia in Ireland. Irish Journal of Psychiatry, 1997(Spring/Summer):12-16.
31. Viale, G, Mechling, L, Maislin, G, et al., Impact of risperidone on the use of health care resources. Psychiatric Services, 1997. 48(9):1153-1159. (Pubitemid 27371963)
32. Albright, PS, Livingstone, S, Keegan, DL, et al., Reduction of Healthcare Resource Utilisation and Costs Following the Use of Risperidone for Patients with Schizophrenia Previously Treated with Standard Antipsychotic Therapy. Clinical Drug Investigation, 1996. 11(5):289-299.
33. Albright, P, Livingstone, S, Keegan, D, et al. Long-term health care resource utilisation and costs before and after initiation of risperidone treatment in patients with chronic schizophrenia. American Psychiatric Association. May 1997.
34. Drummond, M, Economic analysis alongside clinical trials; an introduction for clinical reseachers, 1994, NHS R& D Directorate and Centre for Health Economics: Leeds & York.
35. Cohen, LJ, Looking beyond the formulary budget in cost-benefit analysis. American Journal of Managed Care, 1997. 3:S11-S17.
36. Maynard, AL, Cookson, RF, Computer Modelling: The need for careful evaluation and public audit. Pharmacoeconomics (submitted), 1998.
37. Davies, A, Langley, PC, Keks, NA, et al., Risperidone vesus Haloperidol: II. Costeffectiveness. Clinical Therapeutics, 1998. 20(1):196-213.
38. Overall, JE, Gorham, DR, The Brief Psychiatric Rating Scale. Psychological Reports, 1962. 10:799-812.
39. Kay, SR, Opler, LA, Lindenmayer, J-P, The positive and negative syndrome scale (PANSS) rationale and standardisation. British Journal of Psychiatry, 1989. 155(Suppl 7):59-65. (Pubitemid 19270851)
40. Bell, M, Nilstein, R, Beam-Goulet, J, et al., The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale: reliability, comparability and predictive validity. Journal of Nervous and Mental Disease, 1992. 180(11):723-728. (Pubitemid 23009554)
41. Song, F, Risperidone in the treatment of schizophrenia: a meta-analysis of randomised controlled trials. Journal of Clinical Psychopharmacology, 1997. 11(1):65-71. (Pubitemid 27146041)
42. Rawlins, MD, Jefferys, DB, United Kingdom Product Licence applications inolving new active substances, 1987-1989: their fate after appeals. British Journal of Clinical Pharmacology, 1993. 35:599-602. (Pubitemid 23181000)
43. Fitton, A, Benfield, P, Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. Pharmacoeconomics, 1993. 4(2):131-156.
44. Torrance, GW, Feeny, D, Utilities and quality-adjusted life years. International Journal of Technology Assessment in Health Care, 1989. 5:559-575. (Pubitemid 20153102)
45. Williams, A, Economics, QALYs and medical ethics: a health economist's perspective, 1994, University of York, Centre for Health Economics: York, UK.
46. Laupacis, A, Feeny, D, Detsky, AS, et al., How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal, 1992. 146(4):473-481.
47. Chouinard, G, Albright, P, Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology, 1997. 17(4):298-307. (Pubitemid 27312429)
48. Janssen, P A J, Niemegeers, C J E, Awouters, F, et al., Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonist properties. Journal of Pharmacology and Experimental Therapeutics, 1988. 244:685-693. (Pubitemid 18076615)
49. Johnstone, EC, et al, Schizophrenia: problems in clinical practice. Lancet, 1993. 341:536-538. (Pubitemid 23066097)
50. Schotte A, Van Baelen B, Treatment of the symptoms of schizophrenia: a meta-analysis comparing Risperidone with other antipsychotic agents. Poster presented at the 9th Biennial Winter Workshop on Schizophrenia, February 7-13, 1998, Davos, Switzerland;
51. Amery W, Zuiderwijk P, Lemmens P and Van Baelen B, Safety profile of Risperidone. Presented at the 10th European College of Neuropsychopharmacology Congress, Vienna, Austria, September 13-17, 1997.
52. Davies, A, Adena, MA, Keks, NA, et al., Risperidone versus Haloperidol: I. Metaanalysis of Efficacy and Safety. Clinical Therapeutics, 1998. 20(1):58-71. (Pubitemid 28126280)
53. Chouinard, G, Ross-Chouinard, A, Annable, L, et al., The Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences, 1980. 7(3):233.
54. Heinrich, K, Kleiser, E, Lehmann, E, et al. Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia. 17th Congress of Collegium Internationale Neuro- Psychopharmacologicum. 1990. Kyoto, Japan.
55. Barcia, D, Ayuso, JL, Herraiz, ML, et al., Calidad de vida en pacientes esquizofrenicos tratados con risperidona. Anales de Psiquiatria, 1996. 12(10):403-412.
56. Addington, DE, Jones, B, Bloom, D, et al., Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clinical Therapeutics, 1993. 15(5):917-926. (Pubitemid 23339784)
57. Strand, L, Downey, W, Health databases in Saskatchewan. Pharmacoepidemiology, ed. B. Strom. 1994, John Wiley and Sons Ltd: West Sussex UK.
58. Le Lorier, J, Petersen, T, Albright, PS. A retrospective cohort study of the RAMQ database to study the impact of risperidone use in the province of Quebec. Canadian Psychiatric Association. 1997.
59. Le Lorier, J. Effect of risperidone on health care resource use in Quebec. APA. September 1997.
60. Finley, PR, Corbitt, JL, Brunsen, GH, et al. Patient outcome analysis of risperidone treatment. Annual Meeting of the American College of Clinical Pharmacy. August 1996. Nashville TN.
61. Thompson, D, Cost of switching from neuroleptics to risperidone and clozapine; a pilot study of the San Diego County Mental Health Services. Clinical Drug Investigation, 1997. 14:428-433. (Pubitemid 27499624)
62. Chouinard, G, Jones, B, Remington, G, et al., A Canadian multicenter placebocontrolled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 1993. 13(1):25-40. (Pubitemid 23030357)